» Articles » PMID: 29104667

Promotion of Anoxia-reoxygenation-induced Inflammation and Permeability Enhancement by Nicotinamide Phosphoribosyltransferase-activated MAPK Signaling in Human Umbilical Vein Endothelial Cells

Overview
Journal Exp Ther Med
Specialty Pathology
Date 2017 Nov 7
PMID 29104667
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies have demonstrated that nicotinamide phosphoribosyltransferase (NAMPT) promoted inflammation and permeability of vascular endothelial cells following cardiopulmonary bypass (CPB). In addition, mitogen-activated protein kinase (MAPK) signaling was activated and contributed to these cell responses. However, the mechanism by which NAMPT regulates cellular inflammation and permeability remains unknown, and whether NAMPT regulates MAPK signaling during this process is also not clear. The present study established an anoxia-reoxygenation (A-R) model using human umbilical vein endothelial cells (HUVECs) and investigated the regulation of MAPK signaling by NAMPT by using small RNA transfection, ELISA and western blot analysis. The results demonstrated that A-R significantly induced the expression levels of NAMPT and cellular permeability-associated proteins, and the release of several inflammatory factors. Furthermore, calcium and MAPK signaling were evidently increased. When the A-R cells were transfected with NAMPT small interfering RNA, the expression of cellular permeability-associated proteins was downregulated, the release of inflammatory factors was decreased, and calcium and MAPK signaling was blocked. These data suggest that NAMPT may activate MAPK signaling to promote A-R-induced inflammation and permeability enhancement of HUVECs. Therefore, the current study indicates that NAMPT may be a potential drug target for A-R-induced endothelial cell injury subsequent to CPB.

Citing Articles

Efficacy of electroacupuncture on myocardial protection and postoperative rehabilitation in patients undergoing cardiac surgery with cardiopulmonary bypass: a systematic review and Meta-analysis.

Xiaoyu Q, Chunai W, Jianjun X, Jie Z, Xiaoting L, Shengshuang D J Tradit Chin Med. 2024; 44(1):1-15.

PMID: 38213234 PMC: 10774734. DOI: 10.19852/j.cnki.jtcm.20230904.003.


Inhibition of Pre-B Cell Colony Enhancing Factor Reduces Lung Injury in Rats Receiving Cardiopulmonary Bypass.

Lu C, Yang W, Zhou J, Zhang Z, Gong Y, Hu F Drug Des Devel Ther. 2021; 15:51-60.

PMID: 33442236 PMC: 7800440. DOI: 10.2147/DDDT.S281554.


Pre-B-cell colony enhancing factor regulates the alveolar epithelial sodium-water transport system through the ERK and AKT pathways.

Xu W, Zhou J, You M, Lu C, Yang W, Gong Y Am J Transl Res. 2019; 11(9):5824-5835.

PMID: 31632551 PMC: 6789215.


Screening common signaling pathways associated with drug resistance in non-small cell lung cancer via gene expression profile analysis.

Sun T, Zhao Q, Zhang C, Cao L, Song M, Maimela N Cancer Med. 2019; 8(6):3059-3071.

PMID: 31025554 PMC: 6558586. DOI: 10.1002/cam4.2190.

References
1.
Liu S, Qiao S, Yuan J, Liu D . Visfatin stimulates production of monocyte chemotactic protein-1 and interleukin-6 in human vein umbilical endothelial cells. Horm Metab Res. 2008; 41(4):281-6. DOI: 10.1055/s-0028-1102914. View

2.
Zakkar M, Guida G, Suleiman M, Angelini G . Cardiopulmonary bypass and oxidative stress. Oxid Med Cell Longev. 2015; 2015:189863. PMC: 4334937. DOI: 10.1155/2015/189863. View

3.
Durandy Y . Minimizing systemic inflammation during cardiopulmonary bypass in the pediatric population. Artif Organs. 2014; 38(1):11-8. DOI: 10.1111/aor.12195. View

4.
Dong X, Liu Y, Du M, Wang Q, Yu C, Fan X . P38 mitogen-activated protein kinase inhibition attenuates pulmonary inflammatory response in a rat cardiopulmonary bypass model. Eur J Cardiothorac Surg. 2006; 30(1):77-84. DOI: 10.1016/j.ejcts.2006.02.040. View

5.
Bajwa E, Yu C, Gong M, Thompson B, Christiani D . Pre-B-cell colony-enhancing factor gene polymorphisms and risk of acute respiratory distress syndrome. Crit Care Med. 2007; 35(5):1290-5. DOI: 10.1097/01.CCM.0000260243.22758.4F. View